Physician profile
Mohammad Ali Faisal
NPI 1801866405
$1,474.38
in general payments reported to CMS, 2019-2025
14 companies · $25.41 in 2025
The $25.41 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $130 · 2021: $243 · 2022: $228 · 2023: $162 · 2024: $251 · 2025: $25.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $454.95 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $440.49 | 2019-2024 | |
| Braintree Laboratories, INC. | $233.97 | 2019-2023 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $97.21 | 2022-2024 | Entyvio |
| Phathom Pharmaceuticals, INC. | $71.54 | 2024-2025 | Voquezna |
| Mauna Kea Technologies, INC. | $32.51 | 2022 | |
| Aimmune Therapeutics, INC. | $30.67 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $21.89 | 2023 | Dupixent |
| Evoke Pharma, INC. | $19.61 | 2020 | |
| Pfizer INC. | $17.26 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.13 | 2022 | |
| Genzyme Corporation | $14.71 | 2024 | |
| Intercept Pharmaceuticals, INC. | $11.49 | 2020 | |
| Merck Sharp & Dohme LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Faisal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.